Expression of gp 100 in melanoma metastases resected before or after treatment with IFNα and IL-2

Journal of Immunotherapy

Volumn 19, Issue 5, 1996, Pages 375-380

  Scheibenbogen, Carmen ^a   Weyers, Imke ^b   Ruiter, Dirk ^c   Willhauck, Martina ^a   Bittinger, Adolfo ^b   Keilholz, Ulrich ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

GP100; Interferon ; Interleukin 2; Melanoma

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN; INTERLEUKIN 2; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY HMB 45; PROTEIN S 100;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; METASTASIS; PRIORITY JOURNAL; REMISSION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REJECTION;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON-ALPHA; INTERLEUKIN-2; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS;

EID: 0029919464     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199609000-00007     Document Type: Article

References (21)

1. Boon T, Gajewski TF, Coulie P. From defined tumor antigens to effective immunization? Immunol Today 1995;16:334-6.
2. Kawakami Y, Eliyahu S. Sakaguchi K, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor in-13. filtrating lymphocytes. J Exp Med 1994;180:347-52.
3. Cox AL, Skipper J, Chen Y, et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell 14. lines. Science 1994;264:716.
4. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Nat Acad Sci 1994;91:6458-62.
5. Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994;153:2807-18.
6. Mohler T, Willhauck M, Scheibenbogen C, Pawlita M, Brossart P, Keilholz U. Restriction of T-cell receptor Vβ repertoire in melanoma metastases responding to immunotherapy. Melanoma Res 1995;5:129-32.
7. Willhauck M, Mohler T, Scheibenbogen C, et al. T cell receptor β variable region diversity in melanoma metastases after IL-2-based immunotherapy. Clin Cancer Res 1996;2:767-72.
8. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989;7:1863-74.
9. Keilholz U, Scheibenbogen C, Tilgen W, et al. IFNct and IL-2 in the treatment of malignant melanoma: a comparison of two phase 19. II trials. Cancer 1993;72:607-14.
10. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
11. Vennegoor C, Hageman P, Van Nouhuijs H, et al. A monoclonal antibody specific for cells of the melanocyte lineage. Am J Pathol 1988;130:179-92.
12. Carrel S, Dore JF, Ruiter D, et al. The EORTC melanoma group 21. exchange program; evaluation of a multicenter monoclonal antibody study. Int J Cancer 1991;48:836-47.
13. Keilholz U, Goey H, Punt CJA, et al. IFNa/IL-2 versus IFNa/IL-2 ± CDDP in advanced melanoma: an EORTC Melanoma cooperative group trial. Proceedings of the ASCO, 1996, abstract no. 1353.
14. Keilholz U, Scheibenbogen C, Stoelben E, Saeger H, Hunstein W. Immunotherapy of metastatic melanoma with IFNa and IL-2: pattern of progression in responders and patients with stable disease without or with resection of residual lesions. Eur J Cancer 1994; 30A:955-8.
15. Adema G, de Boer AJ, van’t Hullenaar R, et al. Melanocyte lin-eage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 1993;143:1579-85.
16. Marineóla FM, Hijazi YM, Fetsch P, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gplOO in metastatic melanoma cell lines and in situ lesions. J Immunother 1996; 3:192-205.
17. Chen YT, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995;92:8125-9.
18. Lehmann F, Marchand M, Hainaut P, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-7.
19. Restifo NP, Marineóla FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996;88:100-8.
20. Scheibenbogen C, Keilholz U, Meuer S, Dengler T, Tilgen W, Hunstein W. Differential expression and release of LFA-3 and ICAM-1 in human melanoma cell lines. Int J Cancer 1993; 54: 494-8.
21. Bakker ABH, Schreurs MWJ, de Boer AJ, et al. Melanocyte lin-eage-specific antigen gplOO is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.